NextCure, Inc. (NXTC) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, NextCure reported revenue of $0. Net income was -$55.8M, or -$19.65 per diluted share. Operating activities generated -$49.6M of cash, leaving -$50.1M of free cash flow. At fiscal year end, NextCure held $50.2M in total assets against $15.2M in total liabilities, including $26.0M of cash and equivalents.
Open the full interactive NextCure financials → Quarterly statements, key ratios, valuation history and price charts.
NextCure Key Stats
| Share Price | $6.28 |
|---|---|
| Market Cap | $33.3M |
| 52-Week Range | $1.60 – $14.27 |
| Shares Outstanding | 5.3 million (basic, 2026 Q2) |
NextCure Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $22.4M | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$41.2M | -$70.8M | -$75.9M | -$67.6M | -$59.7M | -$57.6M |
| Pre-Tax Income | -$36.6M | -$69.4M | -$74.7M | -$62.7M | -$55.7M | -$55.8M |
| Income Tax | — | — | — | — | — | $0 |
| Net Income | -$36.6M | -$69.4M | -$74.7M | -$62.7M | -$55.7M | -$55.8M |
| Diluted EPS | -$15.96 | -$30.12 | -$32.28 | -$27.00 | -$23.88 | -$19.65 |
NextCure Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$8.6M | -$9.4M | -$9.8M | -$14.9M |
| Diluted EPS | -$3.22 | -$3.32 | -$1.87 | -$2.80 |
NextCure Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $32.8M | $12.3M | $26.6M | $13.1M | $27.7M | $26.0M |
| Current Assets | $288.0M | $227.8M | $164.0M | $112.7M | $71.8M | $43.7M |
| Total Assets | $306.6M | $242.4M | $184.2M | $128.0M | $80.9M | $50.2M |
| Current Liabilities | $10.3M | $6.6M | $9.1M | $6.9M | $9.6M | $10.6M |
| Total Long-Term Debt | $3.5M | — | — | — | — | — |
| Total Liabilities | $12.9M | $9.0M | $16.6M | $13.6M | $15.4M | $15.2M |
| Shareholders' Equity | $293.7M | $233.4M | $167.5M | $114.4M | $65.5M | $34.9M |
NextCure Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$45.0M | -$57.2M | -$53.9M | -$53.0M | -$40.8M | -$49.6M |
| Cash From Investing | $43.5M | $36.6M | $68.0M | $39.3M | $55.3M | $25.6M |
| Cash From Financing | -$1.4M | -$3.3M | $200,000 | $154,000 | $144,000 | $22.3M |
| Free Cash Flow | -$52.1M | -$59.6M | -$56.0M | -$53.8M | -$41.3M | -$50.1M |
Figures from NextCure's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full NextCure financials page for every line item.
NextCure Company Profile
| Ticker | NXTC |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Baltimore, Maryland |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001661059 |
Frequently Asked Questions
What was NextCure's revenue in fiscal 2025?
NextCure (NXTC) reported revenue of $0 for fiscal 2025.
What is NextCure's annual revenue history?
NextCure's annual revenue by fiscal year: 2020: $22.4M; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was NextCure's net income in fiscal 2025?
NextCure reported net income of -$55.8M for fiscal 2025.
What was NextCure's earnings per share (EPS) in fiscal 2025?
NextCure's diluted EPS was -$19.65 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did NextCure generate in fiscal 2025?
NextCure generated -$50.1M of free cash flow in fiscal 2025.
What was NextCure's revenue last quarter?
In its most recent reported quarter (2026 Q2), NextCure reported revenue of $0.
How many shares of NextCure are outstanding?
NextCure reported a weighted average of 5.3 million basic shares outstanding in 2026 Q2.
What is NextCure's market cap?
Based on its latest closing price, NextCure (NXTC) has a market capitalization of about $33.3M.
When does NextCure's fiscal year end?
NextCure's fiscal year end, as registered with the SEC, is December 31.
Where is NextCure headquartered?
NextCure lists its business address in Baltimore, Maryland in its SEC filings.